retatrutide clinical trial weight loss results just posted Phase 3 showing up to 30% body over 80 weeks. That is approaching bariatric surgery territory, from a medication., It targets three hormone pathways: Retatrutide Achieves Up to 30.3%

In the gastrointestinal tract, GLP-1 delays gastric emptying through vagal activation and effects on smooth muscle, increases beta cell proliferation and survival as well as glucose-dependent insulin secretion, suppresses glucagon secretion, and reduces hepatic fat accumulation through fatty acid oxidation as well as hepatic gluconeogenesis [43]

Crosstalk between autophagy and metabolic regulation of cancer stem cells

There is also a tentative link between MTHFR mutations and dementia

& Pacher, P

But unlike insulin, they dont cause weight gain or carry a significant risk of dangerously low blood sugar. Second, GLP-1 medications are showing excellent results for weight management